SCHEMBL1839614

SCHEMBL1839614

COc1cc(Cl)ccc1P(c1ccccc1)c1ccc(Cl)cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
TRPV4 Q9HBA0 1/20 0.41
AVPR2 P30518 1/20 0.40
GPR27 Q9NS67 1/20 0.40
TSHR P16473 1/20 0.40
GRIK1 P39086 1/20 0.40
ALDH1A1 P00352 3/20 0.40
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
SLC6A3 Q01959 4/20 0.39
KCNH2 Q12809 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP19A1 P11511 1/20 0.38
KDM4E B2RXH2 2/20 0.38
KCNMA1 Q12791 1/20 0.38
HIF1A Q16665 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668348 0.85 TRPV4 (0.48) FLT1FLT4KDRTRPV4ALDH1A1
SCHEMBL1834933 0.81 ACHE (0.48) ALDH1A1KDM4EKCNMA1MEN1KMT2A
SCHEMBL1834676 0.81 CA12 (0.48) ALDH1A1CYP2D6KDM4EMEN1KMT2A
SCHEMBL16005619 0.79 CNR2 (0.41) FLT1FLT4KDRTRPV4ALDH1A1
SCHEMBL1837860 0.79 CA12 (0.40) SLC6A4KCNH2MEN1KMT2ACYP3A4
SCHEMBL30992110 0.77 CA1 (0.50) TSHRALDH1A1KMT2AL3MBTL1CYP3A4
SCHEMBL476857 0.77 CA1 (0.50) TSHRALDH1A1KMT2AL3MBTL1CYP3A4
SCHEMBL2159642 0.77 CYP3A4 (0.41) FLT1FLT4KDRGPR27TSHR
SCHEMBL26454178 0.76 CA12 (0.40) SLC6A4KCNH2MEN1KMT2ACYP3A4
SCHEMBL8459532 0.76 CA1 (0.48) TSHRALDH1A1KMT2AL3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 FLT1 4556/4885FLT4 3115/4885KDR 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.